RVRob A. Voskuyl

Rob A. Voskuyl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rob A. Voskuyl has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood–brain barriers studied with (R)-[11C]verapamil positron emission tomography

    by Julia Müllauer, Claudia Kuntner, Martin Bauer, Jens P Bankstahl, Markus Müller, Rob A Voskuyl, Oliver Langer, Stina Syvänen

    This study investigated the influence of P-glycoprotein (P-gp) inhibitor tariquidar on the pharmacokinetics of P-gp substrate radiotracer (R)-[11C]verapamil in plasma and brain of rats and humans by means of positron emission tomography (PET).


  • Open Access

    [11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein

    by Femke E Froklage, Stina Syvänen, N Harry Hendrikse, Marc C Huisman, Carla Fm Molthoff, Yoshihiko Tagawa, Jaap C Reijneveld, Jan J Heimans, Adriaan A Lammertsma, Jonas Eriksson, et al.

    Background: [11C]Flumazenil and positron emission tomography (PET) are used clinically to assess gamma-aminobutyric acid (GABA)-ergic function and to localize epileptic foci prior to resective surgery. Enhanced P-glycoprotein (P-gp) activity has been reported in epilepsy and this may confound interpretation of clinical scans if [11C]flumazenil is a P-gp substrate. The purpose of this study was to investigate whether [11C]flumazenil is a P-gp substrate. Methods: [11C]Flumazenil PET scans were performed in wild type (WT) (n = 9) and Mdr1a/1b, (the genes that encode for P-gp) double knockout (dKO) (n = 10) mice, and in naive rats (n = 10). In parallel to PET scanning, [11C]flumazenil plasma concentrations were measured in rats. For 6 of the WT and 6 of the dKO mice a second, [11C]flumazenil scan was acquired after administration of the P-gp inhibitor tariquidar. Cerebral [11C]flumazenil concentrations in WT and Mdr1a/1b dKO mice were compared (genetic disruption model). Furthermore, pre and post P-gp-blocking cerebral [11C]flumazenil concentrations were compared in all animals (pharmacological inhibition model). Results: Mdr1a/1b dKO mice had approximately 70% higher [11C]flumazenil uptake in the brain than WT mice. After administration of tariquidar, cerebral [11C]flumazenil uptake in WT mice increased by about 80% in WT mice, while it remained the same in Mdr1a/1b dKO mice. In rats, cerebral [11C]flumazenil uptake increased by about 60% after tariquidar administration. Tariquidar had only a small effect on plasma clearance of flumazenil. Conclusions: The present study showed that [11C]flumazenil is a P-gp substrate in rodents. Consequently, altered cerebral [11C]flumazenil uptake, as observed in epilepsy, may not reflect solely GABAA receptor density changes but also changes in P-gp activity.


  • Open Access

    [11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats

    by Joost Verbeek, Jonas Eriksson, Stina Syvänen, Maaike Labots, Elizabeth C M de Lange, Rob A Voskuyl, Martinus P J Mooijer, Marissa Rongen, Adriaan A Lammertsma, Albert D Windhorst

    At present, several positron emission tomography (PET) tracers are in use for imaging P-glycoprotein (P-gp) function in man. At baseline, substrate tracers such as R-[11C]verapamil display low brain concentrations with a distribution volume of around 1. [11C]phenytoin is supposed to be a weaker P-gp substrate, which may lead to higher brain concentrations at baseline. This could facilitate assessment of P-gp function when P-gp is upregulated. The purpose of this study was to synthesize [11C]phenytoin and to characterize its properties as a P-gp tracer.


  • Open Access

    (R)-[11C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus

    by Stina Syvänen, Gert Luurtsema, Carla Fm Molthoff, Albert D Windhorst, Marc C Huisman, Adriaan A Lammertsma, Rob A Voskuyl, Elizabeth C de Lange

    Increased functionality of efflux transporters at the blood-brain barrier may contribute to decreased drug concentrations at the target site in CNS diseases like epilepsy. In the rat, pharmacoresistant epilepsy can be mimicked by inducing status epilepticus by intraperitoneal injection of kainate, which leads to development of spontaneous seizures after 3 weeks to 3 months. The aim of this study was to investigate potential changes in P-glycoprotein (P-gp) expression and functionality at an early stage after induction of status epilepticus by kainate.


  • Open Access

    Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography

    by Lia C. Liefaard, Bart A. Ploeger, Carla F. M. Molthoff, Hugo W. A. M. De Jong, Jouke Dijkstra, Louise Van Der Weerd, Adriaan A. Lammertsma, Meindert Danhof, Rob A. Voskuyl

    Summary: Purpose:  The purpose of the present investigation was to quantify alterations in GABAA receptor density in vivo in rats subjected to amygdala kindling.Methods:  The GABAA receptor density was quantified by conducting a [11C]flumazenil (FMZ) positron emission tomography (PET) study according to the full saturation method, in which each animal received a single injection of FMZ to fully saturate the GABAA receptors. Subsequently, the concentration‐time curves of FMZ in blood [using high‐pressure liquid chromatography with UV detector (HPLC‐UV) or high‐performance liquid chromatography coupled to tandem mass spectrometry (LC/MS/MS)] and brain (with PET‐scanning) were analyzed by population modeling using a pharmacokinetic model, containing expressions to describe the time course of FMZ in blood and brain.Results:  The GABAA receptor density (Bmax) in kindled rats was decreased by 36% compared with controls. This is consistent with a reduction of 28% in electroencephalography (EEG) effect of midazolam in the same animal model, suggesting that a reduced number of GABAA receptors underlies the decreased efficacy of midazolam. Furthermore, receptor affinity (KD) was not changed, but the total volume of distribution in the brain (VBr), is increased to 178% of control after kindling, which might indicate an alteration in the transport of FMZ across the blood–brain barrier.Conclusions:  Both the GABAA receptor density (Bmax), and possibly also the blood–brain barrier transport of FMZ (VBr) are altered after kindling. Furthermore, this study indicates the feasibility of conducting PET studies for quantifying moderate changes in GABAA receptor density in a rat model of epilepsy in vivo.


  • Open Access

    Decreased Efficacy of GABAA‐receptor Modulation by Midazolam in the Kainate Model of Temporal Lobe Epilepsy

    by Lia C. Liefaard, Rou‐Afza F. Gunput, Meindert Danhof, Rob A. Voskuyl

    Summary: Purpose: The objective of this investigation was to characterize quantitatively the time‐dependent changes in midazolam (MDL) efficacy in the silent period after induction of status epilepticus (SE) in rats. The changes in MDL efficacy were correlated to changes in ex vivo GABAA‐receptor expression. Methods: MDL efficacy was quantified by pharmacokinetic–pharmacodynamic (PK‐PD) modeling by using the β‐frequency of the EEG as PD end point. Two PK‐PD experiments were performed in each animal: the first experiment before and the second experiment at either day 4 or day 14 after SE. SE was induced by repetitive intraperitoneal injections with kainate. GABAA‐receptor expression was determined by ex vivo autoradiography with [3H]flumazenil. Results: The concentration versus EEG effect relation of midazolam was successfully described by the sigmoidal Emax model. The maximal effect on the β‐frequency of the EEG (Emax) was reduced to 51.6 ± 35.6% and 25.8 ± 33.7% of the original value at 4 and 14 days after induction of SE. The ex vivo study with [3H]flumazenil showed that the observed reductions in Emax were paralleled by a reduction in GABAA‐receptor density. Conclusions: The efficacy of MDL is decreased in the silent period after SE, which can be partly accounted for by a reduction in GABAA‐receptor density.


  • Population Pharmacokinetic Analysis for Simultaneous Determination of B max and K D In Vivo by Positron Emission Tomography

    by Lia C. Liefaard, Bart A. Ploeger, Carla F. M. Molthoff, Ronald Boellaard, Adriaan A. Lammertsma, Meindert Danhof, Rob A. Voskuyl

    Changes in GABAA-receptor density and affinity play an important role in many forms of epilepsy. A novel approach, using positron emission tomography (PET) and [C-11]flumazenil ([C-11]FMZ), was developed for simultaneous estimation of GABAA-receptor properties, characterized by B max and K D. Following an injection of [C-11]FMZ (dose range: 1–2,000 μg) to 21 rats, concentration time curves of FMZ in brain (using PET) and blood (using HPLC-UV) were analyzed simultaneously using a population pharmacokinetic (PK) model, containing expressions to describe the time course of the plasma concentration (including distribution to the body), the brain distribution, and the specific binding within the brain. Application of this method in control rats resulted in estimates of B max and K D (14.5 ± 3.7 ng/ml and 4.68 ± 1.5 ng/ml, respectively). The proposed population PK model allowed for simultaneous estimation of B max and K D for a group of animals using single injection PET experiments per animal.